Ortho-McNeil™, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc strives to provide innovative, high quality, safe and effective treatments to healthcare professionals in primary care, hospitals and other care facilities.
 
Ortho-McNeil™, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc.
Home
Our Company
Innovation and Research
Our Products
Therapy Areas
Professional Resources
News Center
Contact Us

 
Tell A Friend
Global Resources
Site Map
Printer Friendly Version
Text Sizes SMALL MEDIUM LARGE

Legal Notice
Privacy Policy
State Regulations


Welcome. Ortho-McNeil™, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc is a healthcare company that draws on the rich patient care heritage of its two sister companies, Ortho-McNeil Pharmaceutical®, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc and Janssen®, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc. ORTHO-McNEIL strives to provide innovate, high quality, safe and effective treatments to advance patient care.

Today, we are involved in hospital and institutional settings. We also recently launched a new unit, PRICARA®, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc dedicated to Primary Care - helping healthcare professionals meet their patients’ needs. Ortho-McNeil currently provides products to treat pain, acid reflux disease and infectious diseases.

We continue to explore new opportunities to develop solutions for unmet health care needs. ORTHO-McNEIL is headquartered in Raritan, New Jersey.

FDA ISSUES APPROVABLE LETTER FOR CEFTOBIPROLE FOR TREATMENT OF COMPLICATED SKIN INFECTIONS

FDA Approves DORIBAX™ (doripenem for injection)

ORTHO-McNEIL supports efforts to provide patients with access to prescription medications and participates in Access2Wellness.

Access2Wellness - Patient Assitance
Access to Free or Discounted Prescription Medications to Those Who Qualify.